Where Global Innovation
and Capital Meet
Sectors Art of CVCConsumerEnergyFinancialHealthIndustrialITMediaServicesStartupsTelecomsTransportUniversity

Global University Venturing

Verve Therapeutics turns to $94m series B

Novo and GV participated in a round that lifted the Harvard, Broad Institute and Penn-linked heart disease drug developer's overall funding to more than $215m.


Jan 20, 2021

Immunocore plots course to $100m IPO

The immunotherapy developer plans to go public in the US having raised $565m since being formed to develop assets of a defunct Oxford spinout.

Jan 20, 2021

Karslake slides into UChicago’s Polsky Center

Christine Karslake is set to lead UChicago’s Polsky Science Ventures unit and will be tasked with setting up a deep tech-focused accelerator.

Jan 20, 2021

Vect-Horus collects $14.5m

The Institute for Neurophysiopathology spinout has completed a series D round.

Jan 20, 2021

US universities launch Academic Accelerator

Indiana University is among four US institutions selected by the US Department of Defense's open national security innovation programme for a new accelerator targeting applied research spinouts.

Jan 20, 2021

A1 Group acquires Invenium

The telecoms group has bought a 51% stake in its portfolio company Invenium, a mobility data analytics company spun out of TU Graz.

Jan 20, 2021

Ampacimon procures Diael in acquisition deal

The insulation breakage measuring device producer is joining Ampacimon having launched out of Polytechnic University of Madrid over ten years ago.

Jan 20, 2021

AltPep unpacks $23.1m round

University of Washington spinout AltPep will use the money to advance work on its lead asset that targets Alzheimer’s disease.

Jan 20, 2021

J-Pharma jacks series D up to $21m

Fidelity provided a $4.8m second tranche after a first close featuring vehicles for Kyushu University and Osaka University.

Jan 19, 2021

Pignato pulls out of Allied Minds

Allied Minds will henceforth operate without a chief executive after Joseph Pignato announced his decision to resign.

Jan 19, 2021

BlueSphere Bio brings in $45.6m

Pitt spinout BlueSphere Bio has attracted an initial $45.6m in series B funding towards a $105m target size.

Jan 19, 2021

Biohaven brings Kleo into the fold

Existing shareholder Biohaven has agreed to purchase the remaining stake in Kleo Pharmaceuticals, a Yale spinout it first backed in 2016.

Jan 19, 2021
© 2025 Mawsonia Ltd. All rights reserved.
test reg

Login

Not yet subscribed?

See your subscription offers here